Pre-Exposure Prophylaxis (PrEP) is an HIV prevention strategy based on a daily pill taken by HIV-negative individuals. PrEP contains two antiretroviral medications-tenofovir and emtricitabine. The brand name for PrEP is Truvada. PrEP is meant to be used in combination with other HIV prevention methods, such as condoms. The Centers for Disease Control and Prevention (CDC) recommends PrEP as an effective method for reducing the risk of HIV infection. PrEP should be considered for those at high risk for contracting HIV. These may include men who have sex with men (MSM), injection drug users, and HIV negative individuals with HIV positive partners.
If you would like to have an update on PrEP at your clinical site, or if you are providing PrEP and would like your site to be included in a PrEP provider directory that will be posted on the Phila Dept. of Public Health Website, please contact Erika Aaron, at erika.aaron@phila.gov